Share: Facebook Twitter LinkedIn
Activity Provided By:

ACHL

RCC Treatment Strategies in a Poor-Risk Patient

Access Activity

Overview / Abstract:

Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.

Expiration

Aug 27, 2022

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Webinar / Webcast / Video

Credits / Hours

.50 AMA PRA Category 1 Credit(s)

Accreditation

ACCME

Presenters / Authors / Faculty

Oguz Akin, MD
Professor of Radiology
Attending Radiologist
Memorial Sloan Kettering Cancer Center
New York, NY

Robert Motzer, MD
Attending Physician, Head, Kidney Cancer Section
Memorial Sloan Kettering Cancer Center
New York, NY

Elizabeth Plimack, MD, MS
Professor, Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA

Jay Raman, MD, FACS
Professor and Chief of Urology
Penn State College of Medicine
Penn State Health Milton S. Hershey Medical Center
Hershey, PA

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy, Nephrology, Radiology / Imagery / Nuclear Medicine, Surgery, Urology

Sponsors / Supporters / Grant Providers

This activity is supported by independent medical education grants from Exelixis, Inc., and Merck & Co., Inc..

Keywords / Search Terms

ACHL CME/CE, CME, CE, Akin, Motzer, Raman, Plimack, Penn State, RCC, ccRCC, renal cell carcinoma, patient case, oncology, radiology, imaging, virtual tumor board, tumor board, lesion, CARMENA, sunitinib, nephrectomy, NCCN, histology, CheckMate 214, KEYNOTE-426, CheckMate 9ER, surgery Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map